US Stock Market Movement: Precigen surged on September 30th due to FDA platform approval and Papzimeos volume increase
Bitget异动解读2026/09/30 17:45Precigen September 30 Surge Interpretation
Keywords: FDA platform certification, Papzimeos volume increase
1. On September 21, 2026, the FDA granted platform technology certification to Precigen’s AdenoVerse immunotherapy platform. This platform has already supported the approved drug Papzimeos. The related certification creates conditions for future drug applications to reuse part of the manufacturing and preclinical knowledge.
2. Disclosed on September 30, 2026: Papzimeos achieved $74.6 million in revenue in the first six months of 2026, with product revenue in Q2 2026 more than doubling quarter-on-quarter.
3. Disclosed on September 30, 2026: Papzimeos is currently the first and only FDA-approved therapy for adult recurrent respiratory papillomatosis. Its European marketing authorization application is under review, and it enjoys an FDA market exclusivity period until August 14, 2032.
(Disclaimer: This content is generated by AI technology based on publicly available information and is for reference only. It does not constitute investment advice.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Daly: High inflation has persisted for too long, the Federal Reserve may need to raise interest rates further
Daly said on Friday that she expects the Federal Reserve will need to raise interest rates further, but like other policymakers, she believes the pace and timing of rate hikes remain uncertain.
Tom Lee and a JPMorgan Manager Call the AI Rout Normal: Will Nasdaq Rally 15%?
US Super Micro Computer rises 11.04%, leading the top traded stocks.
Crypto prices
More
